ASCENTA CAPITAL
ASCENTA CAPITAL is a Series A, Series B and Series C+ fund in the US writing $2M–$30M checks into biotechnology and healthcare-tech.
- Stages
- Series A, Series B, Series C+
- Sectors
- biotechnology, healthcare-tech
- Check size
- $2M–$30M
- Invests in
- US-wide
- Actively investing
- Yes
- Founded
- 2023
- Assets under management
- $325M
- Website
- ascentacap.com
Thesis
Ascenta Capital is a venture capital firm founded in 2023, specializing in the biotechnology sector with headquarters in the United States. The firm focuses on investing in development-stage biotechnology companies, particularly those moving from preclinical science to early human safety and efficacy data. Their investment strategy centers on "platform-first" companies that leverage a single core technology to develop multiple medicines, thereby balancing risk through diversified pipelines. Ascenta Capital is therapeutic area agnostic but prioritizes companies in Phase 1 and Phase 2 clinical trials. The firm aims to be a lead or co-lead investor, providing strategic capital and operational support across clinical, regulatory, manufacturing, scientific, and capital strategy. The inaugural fund, Ascenta Capital Fund I, closed at $325 million in October 2025. The typical check size ranges from $2 million to $30 million.
Common questions
Does ASCENTA CAPITAL invest at the Series A stage?
Yes. ASCENTA CAPITAL lists Series A, Series B and Series C+ among the stages it invests in.
What check size does ASCENTA CAPITAL write?
ASCENTA CAPITAL writes $2M–$30M checks.
Where does ASCENTA CAPITAL invest?
ASCENTA CAPITAL invests in the US.